Analyse
Fundierte Analysen zu Pharmamärkten, Lieferketten, Technologie und Regulierung
Analyse
1. Sept. 2026•1 Min. Lesezeit
Daewoong’s Botulinum Toxin NABOTA Hits 1 Trillion KRW Cumulative Sales, Eyes Global Expansion
Daewoong Pharmaceutical reports its botulinum toxin NABOTA surpassed 1 trillion KRW in cumulative sales within 12 years, positioning it as a global blockbuster. The firm plans to boost production and expand its aesthetic portfolio.
Analyse
1. Sept. 2026•1 Min. Lesezeit
Il-yang Pharma's DodamDodam Triple Vitaac sales rise over 70% in H1
Il-yang Pharmaceutical reports its OTC children's supplement DodamDodam Triple Vitaac posted ~1.8 bn KRW sales in the first half of the year, a growth of more than 70% YoY.
Analyse
1. Sept. 2026•1 Min. Lesezeit
ST Pharm projected Q2 earnings beat expectations on oligonucleotide sales
ST Pharm is forecast to post Q2 revenue of 103.4 billion KRW and operating profit of 20.8 billion KRW, up 51.5% and 60.8% YoY, driven by oligonucleotide shipments and new orders.
Analyse
1. Sept. 2026•1 Min. Lesezeit
HK Innoen's K‑Cap (Tegoprazan) Targets US Launch, Boosts Growth Prospects
Domestic drug K‑Cap (tegoprazan) is nearing US market entry, with analysts seeing royalty revenue and a shift to global growth for HK Innoen.
Analyse
1. Sept. 2026•1 Min. Lesezeit
Samjin Pharma to Normalize HydraSec Supply After MFDS Pediatric Indication Withdrawal
Following MFDS removal of pediatric use for diacetyl hexyl smectite, demand shifted to HydraSec, causing shortages; Samjin Pharma expects supply normalization this week.
Analyse
1. Sept. 2026•1 Min. Lesezeit
Pharmacy Compounding and OTC Sales Stabilize in Korea Week 27, Minor Declines in Key Categories
Compounding volumes held steady while OTC sales slipped slightly in Korea's week 27, with modest drops across cough, throat, pain and digestive product lines.
Analyse
31. Aug. 2026•1 Min. Lesezeit
AstraZeneca pays $200M upfront to Sino Biopharma for PDE3/4 inhibitor rights
AstraZeneca has paid $200 million to Sino Biopharmaceutical and secured non‑China rights to PDE3/4 inhibitor TQC3721, aiming to develop a COPD candidate against Merck’s Ohtuvayre.
Analyse
31. Aug. 2026•1 Min. Lesezeit
DUOLAC launches travel‑focused probiotic campaign with creator Bunny Bottle
Probiotic brand DUOLAC teams up with travel influencer Bunny Bottle to promote its new DUOLAC STOP travel pack, with online and offline promotions through September.
Analyse
31. Aug. 2026•1 Min. Lesezeit
GC Green Cross and Korea Vaccine Sign MOU for Vaccine CMO Collaboration
GC Green Cross and Korea Vaccine have signed an MOU to cooperate on contract manufacturing of vaccines, including prefilled syringe production and diversification of flu‑vaccine output.
Analyse
31. Aug. 2026•1 Min. Lesezeit
Celltrion Biosimilars Gain Momentum in Europe, Omliclo Reaches 16% Share Q1
Celltrion's follow‑on biosimilars are expanding in Europe, with Omliclo achieving about 16% market share in Q1 2024, driven by a first‑mover strategy and direct sales network.
Analyse
31. Aug. 2026•1 Min. Lesezeit
Hanmi Pharm Q2 earnings buoyed by one‑off Lilly tech transfer payment, core sales lag
Hanmi Pharm's Q2 results show strong growth due to a KRW 112.9 bn upfront from Eli Lilly for GLP‑2 candidate sonepegLutide, but analysts say core sales remain weak.
Analyse
31. Aug. 2026•1 Min. Lesezeit
Il-yang Pharma's Noltec Plus sees 13.7% Q2 prescription sales rise
Noltec Plus outpatient sales hit 2.4 billion KRW in Q2, up 13.7% QoQ, with monthly prescriptions soaring to 860 million KRW in June.